此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

REGN5668 联合 Cemiplimab 或 REGN4018 治疗复发性卵巢癌成年女性的研究

2026年9月20日 更新者:Regeneron Pharmaceuticals

REGN5668(MUC16xCD28,一种共刺激双特异性)与 Cemiplimab 或 REGN4018 (MUC16xCD3) 联合给药的 1/2 期研究

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

研究概览

研究类型

介入性

注册 (估计的)

612

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • São Paulo、巴西、01509-010
        • 招聘中
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、巴西、90619-900
        • 招聘中
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos、São Paulo、巴西、14784-400
        • 招聘中
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba、São Paulo、巴西、18065-100
        • 招聘中
        • Unimed Sorocaba
    • Vlaams-Brabant
      • Leuven、Vlaams-Brabant、比利时、3000
        • 招聘中
        • Universitair Ziekenhuis Leuven
      • Villejuif、法国、94805
        • 招聘中
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite、Auvergne-Rhône、法国、69310
        • 招聘中
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon、Bourgogne-Franche-Comté、法国、21000
        • 招聘中
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux、New Aquitaine、法国、33076
        • 招聘中
        • Institut Bergonie
    • Normandy
      • Caen、Normandy、法国、14076
        • 招聘中
        • Centre Francois Baclesse (CFB)
    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope Comprehensive Cancer Center
      • Irvine、California、美国、92618
        • 招聘中
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange、California、美国、92868
        • 招聘中
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa、Florida、美国、33612
        • 完全的
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago、Illinois、美国、60637
        • 招聘中
        • University of Chicago Medical Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Karmanos Cancer Institute
    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle、Washington、美国、98109
        • 招聘中
        • Seattle Cancer Care Alliance at South Lake Union - G3630
      • Girona、西班牙、17007
        • 招聘中
        • Institut Catala dOncologia Girona
      • Madrid、西班牙、28040
        • 招聘中
        • Hospital Universitario Fundacion Jimenez
      • Madrid、西班牙、28040
        • 招聘中
        • Ciudad Universitaria
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela、A Coruna、西班牙、15706
        • 招聘中
        • Hospital Clinico Universitario Santiago de Compostela

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

其他名称:
  • ubletamig

Administer per the protocol

其他名称:
  • REGN2810
  • Libtayo®

Administer per the protocol

实验性的:Module 2

REGN5668 and ubamatamab

Administer per the protocol

其他名称:
  • ubletamig

Administer per the protocol

其他名称:
  • 雷根4018

Administer per the protocol

其他名称:
  • Kevzara®

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Dose Limiting Toxicities (DLT)
大体时间:42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
大体时间:21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
大体时间:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
大体时间:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
大体时间:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
大体时间:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
大体时间:Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
大体时间:Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

次要结果测量

结果测量
措施说明
大体时间
ORR based on RECIST 1.1
大体时间:Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
大体时间:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年12月8日

初级完成 (估计的)

2028年11月8日

研究完成 (估计的)

2028年11月8日

研究注册日期

首次提交

2020年10月9日

首先提交符合 QC 标准的

2020年10月9日

首次发布 (实际的)

2020年10月19日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月20日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 共享时间框架

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共享访问标准

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅